A5066285433- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- CNS Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Alzheimer's disease research and treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cancer Immunotherapy and Biomarkers
- Immunodeficiency and Autoimmune Disorders
- Parathyroid Disorders and Treatments
- Blood disorders and treatments
- Histone Deacetylase Inhibitors Research
- Bacterial Identification and Susceptibility Testing
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Cytomegalovirus and herpesvirus research
- Chronic Myeloid Leukemia Treatments
- Colorectal Cancer Treatments and Studies
- Frailty in Older Adults
- Neuroendocrine Tumor Research Advances
- Statistical Methods in Clinical Trials
Mayo Clinic in Arizona
2024
WinnMed
2024
Mayo Clinic
2024
Indiana University Health
2022-2023
Indiana University School of Medicine
2022-2023
Indiana University – Purdue University Indianapolis
2022-2023
University of Massachusetts Chan Medical School
2018-2021
Baystate Medical Center
2018-2021
John Wiley & Sons (United States)
2019
Baystate Health
2019
Multiagent chemoimmunotherapy remains the standard of care treatment for Burkitt lymphoma leading to a cure in majority cases. However, frontline regimens are associated with significant risk related toxicity especially elderly and immunocompromised patients. Additionally, prognosis dismal refractory/relapsed lymphoma. Thus, novel therapies required not only improve outcomes relapsed/refractory but also minimize toxicities. Recurrent genomic changes signalling pathway alterations that have...
Drug-induced thrombotic microangiopathies (DTMAs) are increasingly being recognized as an important category of (TMAs). Cancer therapeutic agents including proteasome inhibitors (PIs) among the most common medications reported to cause DTMA. PIs could DTMA either by immune mechanism or dose-dependent/cumulative toxicity. Eleven cases have been with bortezomib and carfilzomib. To best our knowledge, only one case has ixazomib due immune-mediated mechanism. Here, we report first...
Frailty has important implications for the care of elderly and how their needs are met.To assess clinicians' acknowledgement frailty in electronic medical records (EMR) impact recognition on advance planning (ACP).We performed a retrospective study 119 patients 65 years or older with moderate severe assessed using validated scale. We reviewed notes to determine if primary team identified obtained data regarding ACP planning. present characteristics outcomes who were as frail compared them...
The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody combination chemotherapy or as single agent treatment indolent non-Hodgkin lymphomas has paved way for development various forms antibodies that act different ways against lymphoma tumor cells. These could directly target surface antigen resulting cells toxicity and killing. Other include antibody-drug conjugates bispecific antibodies. role therapeutic will be reviewed, highlighting their mode...
Intensified chemoimmunotherapy regimens are often used in young patients with double hit and triple lymphoma (DHL/THL) despite no survival benefit compared to R-CHOP. Favorable retrospective reports on the application of CODOX-M/IVAC-R subject selection bias as only fit can tolerate this treatment. We conducted a analysis investigate outcome differences between DA-EPOCH-R DHL/THL aged 60 years or younger. 113 were identified; (N=49) (N=64). 80% (39/49) achieved complete (CR) after completing...
7516 Background: Immune effector cell hemophagocytic lymphohistiocytosis IEC-HS is a complication of CAR T therapy (CART). This study aims to look at the outcomes CART patients who develop IEC-HS. Methods: Patients developed after receiving and without (nonCART) between December 2020 March 2022 were included. Results: The 20 older than 25 nonCART patients. Peak ferritin, fibrinogen, CRP, serum creatinine transaminases similar 2 group. had lower white blood count platelets bilirubin more like...
7067 Background: High intensity induction with regimens such asDA-EPOCH-R, CODOX-M/IVAC-R and HyperCVAD are often used for young patients DHL/THL despite no overall survival (OS) benefit compared to R-CHOP. Reports on the application of subject selection bias as only fit can tolerate it. We aimed investigate outcomes difference between DA-EPOCH-R in ≤ 60 years diagnosed via FISH. Methods: Retrospective review from Mayo Clinic July15 th 2010-October19th 2023 treated or at age up years. Event...